Inventiva S.A. ADR (IVA): Price and Financial Metrics
GET POWR RATINGS... FREE!
IVA Stock Summary
- IVA's went public 1.72 years ago, making it older than merely 4.21% of listed US stocks we're tracking.
- Of note is the ratio of Inventiva SA's sales and general administrative expense to its total operating expenses; merely 7.37% of US stocks have a lower such ratio.
- With a price/sales ratio of 48.64, Inventiva SA has a higher such ratio than 96.14% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Inventiva SA, a group of peers worth examining would be CDTX, CBIO, XCUR, ORGS, and ZYME.
- Visit IVA's SEC page to see the company's official filings. To visit the company's web site, go to www.inventivapharma.com.
IVA Stock Price Chart Interactive Chart >
IVA Price/Volume Stats
| Current price | $5.75 | 52-week high | $15.78 |
| Prev. close | $5.67 | 52-week low | $5.25 |
| Day low | $5.67 | Volume | 2,100 |
| Day high | $6.20 | Avg. volume | 17,536 |
| 50-day MA | $8.60 | Dividend yield | N/A |
| 200-day MA | $11.92 | Market Cap | 235.03M |
Inventiva S.A. ADR (IVA) Company Bio
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
Latest IVA News From Around the Web
Below are the latest news stories about Inventiva SA that investors may wish to consider to help them evaluate IVA as an investment opportunity.
Wall Street Analysts Think Inventiva S.A. Sponsored ADR (IVA) Could Surge 153%: Read This Before Placing a BetThe consensus price target hints at a 152.7% upside potential for Inventiva S.A. Sponsored ADR (IVA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
Analysts Are Bullish on These Healthcare Stocks: Veru (VERU), Outlook Therapeutics (OTLK)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Veru (VERU – Research Report), Outlook Therapeutics (OTLK – Research Report) and Inventiva (IVA – Research Report) with bullish sentiments. Veru (VERU) In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Veru, with a price target of $21.00. The company's shares closed last Monday at $6.07, close to its 52-week low of $4.37. According to TipRanks. |
Inventiva reports cash position and revenues for Full-Year 2021Cash position2 at €95.4m as of December 31, 2021, compared to €105.7m on September 30, 2021, and €113.0m on December 31, 2020Revenues of €4.2m in 2021 compared to €0.4m in 2020 Daix (France), Long Island City (New York, United States), February 14, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unm |
Inventiva gets 4M milestone payment from AbbVie in cedirogant trial to treat psoriasisInventiva (IVA) received a 4M milestone payment from AbbVie (ABBV) following the inclusion of the first patient with psoriasis in an ongoing phase 2b trial with |
Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiationDaix (France), Long Island City (New York, United States), January 31, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced the receipt of a €4 million milestone payment from AbbVie. It follows the inclusion of the first patient with psori |
IVA Price Returns
| 1-mo | -35.54% |
| 3-mo | -52.68% |
| 6-mo | -56.41% |
| 1-year | -59.65% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -57.91% |
| 2021 | -5.79% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...